Silver Spring, Maryland – REGENXBIO Inc. recently held its Q2 2024 Earnings Conference Call, providing updates on the company’s financial and operational performance. Key executives, including the CLOCurran Simpson – President and CEOSteve Pakola, and CFO Vit Vasista, discussed the progress made in advancing the pipeline of AAV therapeutics.

During the call, Patrick Christmas, the Chief Legal Officer of REGENXBIO, highlighted the financial and operating results for the second quarter of 2024. The company emphasized forward-looking statements regarding financial outlook, regulatory plans, and product development strategies.

Curran Simpson, the President and CEO of REGENXBIO, shared updates on the company’s priority programs, including RGX-202 for Duchenne, AbbVie RGX-314 for wet AMD and diabetic retinopathy, and RGX-121 for MPS II. Significant progress has been made in advancing each program towards pivotal stage clinical trials and future commercialization.

Dr. Steve Pakola, the Chief Medical Officer, provided updates on clinical programs, highlighting positive data for RGX-202 demonstrating consistent microdystrophin expression across treated patients. The company aims to be the next approved gene therapy for Duchenne and has made strides in manufacturing capabilities for RGX-202.

In the collaboration with AbbVie on RGX-314, significant advancements have been made in suprachoroidal trials for diabetic retinopathy and wet AMD. Plans for an end-of-Phase 2 meeting with the FDA have been accelerated, with the initiation of pivotal trials expected in the first half of 2025. The expansion of the ALTITUDE trial to include patients with diabetic macular edema further extends the global potential of RGX-314.

Vit Vasista, the CFO, provided insights into the company’s financial position, highlighting an increase in cash reserves to support operations into 2026. The company remains focused on advancing therapies to address unmet needs and generate value for shareholders.

Overall, REGENXBIO continues to make significant progress in its pipeline of AAV therapeutics, with a strong focus on advancing innovative gene therapies for various medical conditions. The company’s achievements and strategic plans position it well for future growth and success in the biopharmaceutical industry.